ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物醫藥B類股
483.155
-13.603
-2.74%
手動刷新
漲家數：
7
跌家數：
23
平家數：
3
市盈率：
- -
高：
496.758
開：
496.758
低：
480.328
收：
496.758
成交量：
1.15億
成交額：
26.12億
市值：
3,069.30億
流通市值：
2,732.98億
資料載入中...
總覽
新聞
瞄準銀屑病市場，諾誠健華ICP-488值多少錢？
新浪证券
·
09/04
交銀國際：創新持續驅動醫藥高增長 承壓板塊邊際改善 盈利預期更趨樂觀
智通财经
·
09/04
同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37
阿斯达克财经
·
09/04
研報掘金丨中金：下調康方生物目標價至120港元，維持「跑贏行業」評級
格隆汇
·
09/04
連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息
中金财经
·
09/04
《大行》大和：康方生物(09926.HK) HARMONi-2中期OS分析達標 略增全球一線NSCLC III期試驗OS成功信心
阿斯达克财经
·
09/04
基石藥業－Ｂ(02616)股價上升5.016%，現價港幣$6.49
阿斯达克财经
·
09/04
創新藥板塊活躍 昂利康漲停
同花顺
·
09/04
更多創新藥有望納入醫保報銷
格隆汇
·
09/04
康方生物盤中升逾8% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果
新浪港股
·
09/04
康方生物(09926)出現大手買入5.5萬股，成交價$98.0，涉資539萬
阿斯达克财经
·
09/04
港股異動 | 康方生物(09926)早盤升逾10% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果
智通财经
·
09/04
中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准
阿斯达克财经
·
09/04
勁方醫藥-B(02595)存倉市值總計19.55億港元 股東將4373.09萬股股票存入渣打銀行(香港)
智通财经
·
09/04
醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？
蓝鲸财经
·
09/03
里程碑醫藥在華獲批觸發200萬美元里程碑付款
投资观察
·
09/03
歸創通橋(02190)9月3日斥資約112.19萬港元回購5.25萬股
智通财经
·
09/03
雲頂新耀(01952.HK)：星必妥®用於治療成人陣發性室上性心動過速急性症狀發作轉復為竇性心律的新藥上市申請在中國獲批
智通财经
·
09/03
倪昕增持億騰嘉和(06998)15萬股 每股作價約1.65港元
智通财经
·
09/03
勁方醫藥-B(02595)9月3日斥資54.64萬港元回購2萬股
智通财经
·
09/03
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664610382","title":"瞄準銀屑病市場，諾誠健華ICP-488值多少錢？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664610382","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664610382?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 15:23","pubTimestamp":1788506580,"startTime":"0","endTime":"0","summary":"患者总人数方面，ICP-488核心覆盖中重度斑块状银屑病适应症，根据公开行业数据与诺诚健华官方披露，中国银屑病患者总规模约866万人，且呈持续上升趋势。其中约32%的患者为中重度斑块状银屑病，具备系统治疗临床需求，对应目标患者总人数约280万人。整体来看，ICP-488采用规范的RCT试验设计，疗效达到现有标准治疗的先进水平，优于常规非劣效品种，因此临床数据质量系数取0.80。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-04/doc-iniqryes4101624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09969","BK0239","BK1574","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664382826","title":"交銀國際：創新持續驅動醫藥高增長 承壓板塊邊際改善 盈利預期更趨樂觀","url":"https://stock-news.laohu8.com/highlight/detail?id=2664382826","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664382826?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:50","pubTimestamp":1788504630,"startTime":"0","endTime":"0","summary":"创新药产业链增速领跑行业，服务板块复苏在各子板块中，创新产业链继续领跑行业：1)港股/A 股CXO 收入整体增长29.2%/25.3%，(扣非)净利润增长23.4%/67.6%，在各子板块中增速领先，汇率波动对表观利润率有一定压力，但行业整体景气度和订单需求处于高位。其中生物药增速远超化药，在板块收入中的占比也进一步提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03329","BK1147","BK1161","BK1515","ZECP","BK1574","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381726","title":"同源康醫藥－Ｂ(02410)股價上升5.029%，現價港幣$6.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381726","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664381726?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 14:05","pubTimestamp":1788501900,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在下午02:05比前收市价上升5.029%，现股价为港币$6.37。至目前为止，今日最高价为$6.37，而最低价为$6.065。总成交量为410.589万股，总成交金额为港币$2.551千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609046129/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02410","09939","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389264","title":"研報掘金丨中金：下調康方生物目標價至120港元，維持「跑贏行業」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389264","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664389264?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 13:33","pubTimestamp":1788499992,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","LU1794554557.SGD","LU0540923850.HKD","LU0348827113.USD","KURE","LU0561508036.HKD","LU0634319403.HKD","LU2399975544.HKD","LU2476274720.SGD","BK1574","LU0348784397.USD","LU0348735423.USD","LU2778985437.USD","LU1720050803.USD","LU0348767384.USD","LU0417516738.SGD","LU0348766576.USD","LU0348783233.USD","LU2476274308.USD","LU2488822045.USD","09926","LU0348825331.USD","LU1961090484.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516902.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664138500","title":"連虧7年半股迪哲醫藥董事長擬減持 A股募資39億零派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138500","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138500?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:34","pubTimestamp":1788492846,"startTime":"0","endTime":"0","summary":"中国经济网北京9月4日讯 迪哲医药 昨日晚间发布关于董事、高级管理人员减持股份计划公告。 迪哲医药称，上述减持对象本次减持数量占其本人本次减持前所持有公司股份数量均不超过25%。 截至减持股份计划预披露公告发布前最后一个交易日，即2026年9月3日，迪哲医药收报60.08元，以此计算，上述减持主体本次减持金额合计预计为2.17亿元。 经计算，迪哲医药上述两次募集资金金额合计为38.99亿元。 迪哲医药自上市以来未分红。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260904/32360003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02846","83188","BK1574","83130","BK1515","VIG","399300","09939","BK4585","02827","159938","BK4588","07233","03130","82846","BK1147","03188","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385068","title":"《大行》大和：康方生物(09926.HK) HARMONi-2中期OS分析達標 略增全球一線NSCLC III期試驗OS成功信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385068","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385068?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:22","pubTimestamp":1788492120,"startTime":"0","endTime":"0","summary":"大和发表研报指，康方生物依沃西一线治疗PD-L1表达阳性 NSCLC三期研究，经独立数据监察委员会评估的预设总生存期期中分析显示，研究达到OS关键次要终点。大和认为，此进一步验证依沃西单抗在一线NSCLC的OS临床获益，成功由强劲的无进展生存期临床获益转化而来。公司先前亦公布早期中期OS HR为0.777。虽然本次中期OS分析的详细数据尚未公布，但大和认为有助于略为提高对其全球一线NSCLC三期试验OS成功的信心，对康方生物评级为“买入”。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542938/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542938/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0348825331.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0561508036.HKD","LU1720050803.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348767384.USD","LU2778985437.USD","LU0348766576.USD","BK1161","KURE","LU0417516571.SGD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0540923850.HKD","LU2488822045.USD","LU0417516738.SGD","09926","LU2476274308.USD","LU0634319403.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU1794554557.SGD","BK1574","LU0348783233.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852713","title":"基石藥業－Ｂ(02616)股價上升5.016%，現價港幣$6.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852713","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852713?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 11:09","pubTimestamp":1788491340,"startTime":"0","endTime":"0","summary":"[上升股]基石药业－Ｂ(02616) 股价在上午11:08比前收市价上升5.016%，现股价为港币$6.49。至目前为止，今日最高价为$6.49，而最低价为$6.2。总成交量为307.65万股，总成交金额为港币$1.964千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609045563/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609045563/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385956","title":"創新藥板塊活躍 昂利康漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385956","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385956?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:57","pubTimestamp":1788490620,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者冯心怡)9月4日早盘，创新药板块表现活跃，昂利康涨停，报27.86元/股，涨幅为9.99%。昂利康坚持“仿制药—改良型新药—创新药”的研发布局。据新华社9月4日消息，国 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260904/c679599107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LNGR","159992","BK1574","IBBQ","BK1161","06978","002940","BK0239","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HART","06978","159992","BK1574","MEDX","BK4588","BK4585","IBBQ","LNGR","BK1161","IHI","ENTL","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664383605","title":"康方生物盤中升逾8% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383605","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:02","pubTimestamp":1788487320,"startTime":"0","endTime":"0","summary":"9月4日，$康方生物$盘中涨超8%。9月3日，康方生物宣布，依沃西单抗头对头对比$K$药一线治疗PD-L1阳性晚期非小细胞肺癌的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-04/doc-iniqrpqw4027860.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1961090484.USD","LU2778985437.USD","LU0348825331.USD","LU0540923850.HKD","LU0348735423.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU2399975544.HKD","LU0417516902.SGD","LU0348827113.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU0634319403.HKD","LU0348783233.USD","BK1574","LU1720050803.USD","09926","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2488822045.USD","LU0417516738.SGD","LU0348767384.USD","LU0348766576.USD","LU0417516571.SGD","BK1161","LU0348784397.USD","LU2476274308.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831303","title":"康方生物(09926)出現大手買入5.5萬股，成交價$98.0，涉資539萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831303","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831303?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:00","pubTimestamp":1788487200,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午10:00出现大手买入，成交量为5.5万，成交价为港币$98.0，涉资539万。至目前为止，股价升7.819%，今日最高价为$100.3，而最低价为$94.6，总成交量为1.16千万股，总成交金额港币$11.407亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609043591/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609043591/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09926","LU0540923850.HKD","LU1794554557.SGD","LU0417516902.SGD","LU0348783233.USD","BK1574","BK1161","LU0417516738.SGD","LU0348735423.USD","LU2488822045.USD","LU0348784397.USD","KURE","LU0634319403.HKD","LU2399975544.HKD","LU0348766576.USD","LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274308.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0348767384.USD","IE00BPRC5H50.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887233","title":"港股異動 | 康方生物(09926)早盤升逾10% 康方生物依沃西與K藥頭對頭研究獲顯著陽性結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887233","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887233?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:35","pubTimestamp":1788485751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物早盘涨超10%。消息面上，9月3日，康方生物宣布，依沃西单抗头对头对比K药一线治疗PD-L1阳性晚期非小细胞肺癌的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491892.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2399975544.HKD","LU0348783233.USD","IE00BPRC5H50.USD","LU0348825331.USD","LU1961090484.USD","LU2476274720.SGD","BK1574","IE00B543WZ88.USD","LU1794554557.SGD","LU0348784397.USD","LU0348767384.USD","LU2476274308.USD","LU0634319403.HKD","LU0417516902.SGD","LU2778985437.USD","BK1161","LU0417516571.SGD","LU1720050803.USD","LU0348827113.USD","09926","LU0561508036.HKD","LU2488822045.USD","LU0417516738.SGD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0348735423.USD","KURE","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664241388","title":"中生製藥(01177.HK)GPC3 ADC臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664241388","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664241388?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 09:24","pubTimestamp":1788485040,"startTime":"0","endTime":"0","summary":"中国生物制药(01177.HK) 公布，集团附属公司正大天晴自主研发的国家1类新药TQB6426“GPC3抗体药物偶联物(ADC)”已获得美国食品药品监督管理局(FDA)的新药临床试验(IND)批准，拟用于晚期恶性肿瘤。目前，全球尚无靶向GPC3的ADC药物获批上市，同类候选产品整体处于临床前及早期临床探索阶段。集团将加速TQB6426的I期临床试验，评估其在晚期恶性肿瘤患者中的安全性、耐受性、药代动力学特征及初步疗效，尽早为全球肝细胞癌及更多实体瘤患者提供新的治疗选择。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-03 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220728114525438_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1542877/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01177","BK1574","BK1515","IE00BZ08YT58.USD","BK1191","BK1521","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1589","01477","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388377","title":"勁方醫藥-B(02595)存倉市值總計19.55億港元 股東將4373.09萬股股票存入渣打銀行(香港)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664388377?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 08:34","pubTimestamp":1788482051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，劲方医药-B(02595)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。该公司股东将4373.09万股股票存入渣打银行(香港)，持股比例增加12.44%。劲方医药此前发布公告，GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌(NSCLC)的II期研究，包括单药疗法、联合EGFR单抗(西妥昔单抗)或联合化疗(培美曲塞)三种治疗方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","09939","BK1161","02595","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803502","title":"醫藥代表退場，基藥目錄「及時雨」能否解藥企之渴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803502","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803502?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 23:41","pubTimestamp":1788450086,"startTime":"0","endTime":"0","summary":"02 8年磨一剑，基药目录送来“及时雨”恰在此时，基药目录更新了。二是基药目录首次纳入创新药。集采中标、医保谈判、基药目录入围构成了药品放量的三大政策通道。白马认为，基药目录的“及时雨”能解药企一时之渴，却解不了长期之渴。当医药代表退场的尘埃落定，当“带金销售”彻底成为过去式，真正能笑到最后的，是那些产品过硬、证据扎实、推广合规的药企。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788329362059116704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1515","09939","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140066454","title":"里程碑醫藥在華獲批觸發200萬美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1140066454","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140066454?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 23:00","pubTimestamp":1788447612,"startTime":"0","endTime":"0","summary":"9月3日（路透社）——Milestone Pharmaceuticals Inc.今日宣布，其用于治疗阵发性室上性心动过速的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。该公司进一步披露，NMPA的此次批准触发了云顶新耀应向Milestone Pharmaceuticals支付的200万美元里程碑付款。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01952","BK1161","MIST","BK4007","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664990874","title":"歸創通橋(02190)9月3日斥資約112.19萬港元回購5.25萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664990874","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664990874?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:19","pubTimestamp":1788437984,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2026年9月3日该公司斥资约112.19万港元回购5.25万股，回购价格为每股21.18至21.52港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","BK1587","BK1583","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787436","title":"雲頂新耀(01952.HK)：星必妥®用於治療成人陣發性室上性心動過速急性症狀發作轉復為竇性心律的新藥上市申請在中國獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787436?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:09","pubTimestamp":1788437371,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01952","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664792879","title":"倪昕增持億騰嘉和(06998)15萬股 每股作價約1.65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664792879","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664792879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:30","pubTimestamp":1788435039,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月1日，倪昕增持亿腾嘉和15万股，每股作价1.6489港元，总金额约为24.73万港元。增持后最新持股数目约为7.63亿股，最新持股比例为37.88%。补充资料：The capacity in which shares are held in box 24 is detailed in box 27. Of the 745,805,568 shares held by Mr. Ni as beneficial owner, he has a direct interest in 644,504,367 shares and holds 30,675,180 Target Share Options under the Target Share Option Scheme. Pursuant to the Merger Agreement and the One-off Share Option Plan, these were converted into 101,301,201 Converted Options. Please refer to the announcement of Edding Genor Group Holdings Limited dated 30 December 2025 for further details.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","06998","BK1161","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879974","title":"勁方醫藥-B(02595)9月3日斥資54.64萬港元回購2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879974","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664879974?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:21","pubTimestamp":1788434461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月3日斥资54.64万港元回购2万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","02595","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":10,"totalSize":345,"code":"91000000","status":"200"}]}}